Actinic keratosis (AK) or lesions of epidermal dysplasia occurring in skin chronically exposed to solar radiation is very prevalent in lighter skin persons, with chronic long-term sun exposure being the major risk factor. With an aging population it is expected that the prevalence of AK will further increase. AK can progress to nonmelanoma skin cancer (NMSC) and is a public health concern. Six leading dermatologists with expertise in AK and NMSC from Germany met to discuss the nature of the disease and the prevention and treatment strategies available to dermatologists today. While cosmetic sunscreen products form an essential element of sun protection strategies, they are not adequate when damage has already been inflicted. Newly developed products of the medical device category offer DNA repair function paired with high sun protection factor (SPF) UV protection. An adjuvant treatment algorithm for various risk levels of AK was developed. For patients with low and moderate risk, sunscreen only is recommended. For patient groups with high and very high risk, a very high photoprotection and photorepair action (DNA repair enzymes) in medical device products all year round is recommended.

Keywords:
Actinic keratosis, Nonmelanoma skin cancer, Photolyase, Medical device, Photoprotection, Photorepair
1.
Marks R: Epidemiology of non-melanoma skin cancer and solar keratosis in Australia: a tale of self-immolation in Elysian fields. Australas J Dermatol 1997;38:S26- S29.
2.
Frost CA, Green AC: Epidemiology of solar keratoses. Br J Dermatol 1994;131:455-464.
3.
Stockfleth E, Terhorst D, Braathen L, et al; Guideline Subcommittee of the European Dermatology Forum: Guidelines for the management of actinic keratosis - update 2011. http://bestpractice.bmj.com/best-practice/monograph/616/diagnosis/guidelines.html (accessed August 25, 2013).
4.
Schaefer I, Augustin M, Spehr C, Reusch M, Kornek T: Prevalence and risk factors of actinic keratoses in Germany - analysis of multisource data. J Eur Acad Dermatol Venereol 2014;28:309-313.
5.
Berman B, Cockerell CJ: Pathobiology of actinic keratosis: ultraviolet-dependent keratinocyte proliferation. J Am Acad Dermatol 2013;68:S10-S19.
6.
Diepgen TL, Brandenburg S, Aberer W, Bauer A, Drexler H, Fartasch M, Malte John, S, Krohn S, Palfner S, Römer W, Schuhmacher-Stock U, Elsner P: Skin cancer induced by natural UV-radiation as an occupational disease - requirements for its notification and recognition. J Dtsch Dermatol Ges 2014;12:1102-1106.
7.
Schmitt J, Seidler A, Diepgen TL, Bauer A: Occupational UV-light exposure increases the risk for the development of cutaneous squamous cell carcinoma: a systematic review and meta-analysis. Br J Dermatol 2011;164:291-307.
8.
Oppel T, Korting HC: Actinic keratosis: the key event in the evolution from photoaged skin to squamous cell carcinoma; therapy based on pathogenetic and clinical aspects. Skin Pharmacol Physiol 2004;17:67-76.
9.
Segen JC: Field cancerization; in Medical Dictionary - The Free Dictionary. McGraw-Hill Concise Dictionary of Modern Medicine. New York, McGraw-Hill, 2002.
10.
Braakhuis BJM, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH: A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003;63:1727-1730.
11.
Brennan JA, Mao, L, Hruban, RH, Boyle, JO, Koch, WM, Sidransky D: Molecular assessment of histopathological staging in squamous cell carcinoma of the head and neck. N Engl J Med 1995;332:429-435.
12.
Chen GJ, Feldman SR, Williford PM, Hester EJ, Kiang SH, Gill I, et al: Clinical diagnosis of actinic keratosis identifies an elderly population at high risk of developing skin cancer. Surg Dermatol 2005;31:43-47.
13.
Mittelbronn MA, Mullins DL, Ramos-Caro FA, Flowers FP: Frequency of pre-existing actinic keratosis in cutaneous squamous cell carcinoma. Int J Dermatol 1998;37:677-681.
14.
Czarnecki D, Meehan CJ, Bruce F, Culjak G: The majority of cutaneous squamous cell carcinomas arise in actinic keratoses. J Cutan Med Surg 2002;6:207-209.
15.
Fernández-Figueras MT, Carrato C, Sáenz X, Puig L, Musulen E, Ferrándiz C, Ariza A: Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol 2015;29:991-997.
16.
Dodson JM, DeSpain J, Hewett JE, Clark DP: Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective. Arch Dermatol 1991;127:1029-1031.
17.
Glogau RG: The risk of progression to invasive disease. J Am Acad Dermatol 2000;42:23-24.
18.
de Laat WL, Jaspers NGJ, Hoeijmakers JHJ: Molecular mechanism of nucleotide excision repair. Genes Dev 1999;13:768-785.
19.
Kraemer KH, Levy DD, Parris CN, Gozukara EM, Moriwaki S, Adelberg S, Seidman MM: Xeroderma pigmentosum and related disorders: examining the linkage between defective DNA repair and cancer. J Invest Dermatol 1994;103(suppl 5):96S-101S.
20.
Ziegler A, Jonason AS, Leffell DJ, Simon JA, Sharma HW, Kimmelman J, Remington L, Jacks T, Brash DE: Sunburn and p53 in the onset of skin cancer. Nature 1994;372:773-776.
21.
Raybaud-Diogène H, Tétu B, Morency R, Fortin A, Monteil RA: p53 overexpression in head and neck squamous cell carcinoma: review of the literature. Eur J Cancer B Oral Oncol 1996;32B:143-149.
22.
Schwarz T, Schwarz A: DNA repair and cytokine responses. J Investig Dermatol Symp Proc 2009;14:63-66.
23.
Aubin F: Mechanisms involved in ultraviolet light-induced immunosuppression. Eur J Dermatol 2003;13:515-523.
24.
Thompson SC, Jolley D, Marks R: Reduction of solar keratoses by regular sunscreen use. N Engl J Med 1993;329:1147-1151.
25.
Naylor MF, Boyd A, Smith DW, Cameron GS, Hubbard D, Neldner KH: High sun protection factor sunscreens in the suppression of actinic neoplasia. Arch Dermatol 1995;131:170-175.
26.
Ou-Yang H, Stanfield J, Cole C, Appa Y, Rigel D: High-SPF sunscreens (SPF ≥70) may provide ultraviolet protection above minimal recommended levels by adequately compensating for lower sunscreen user application amounts. J Am Acad Dermatol 2012;67:1220-1227.
27.
Neale R, Williams G, Green A: Application patterns among participants randomized to daily sunscreen use in a skin cancer prevention trial. Arch Dermatol 2002;138:1319-1325.
28.
Ulrich C, Jürgensen JS, Degen A, Hackethal M, Ulrich M, Patel MJ, Eberle J, Terhorst D, Sterry W, Stockfleth E: Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 2009;161(suppl 3):78-84.
29.
Holick MF: Sunlight, ultraviolet radiation, vitamin D and skin cancer: how much sunlight do we need? Adv Exp Med Biol 2014;810:1-16.
30.
Terushkin V, Bender A, Psaty EL, Engelsen O, Wang SQ, Halpern AC: Estimated equivalency of vitamin D production from natural sun exposure versus oral vitamin D supplementation across seasons at two US latitudes. J Am Acad Dermatol 2010;62:929.e1-e9.
31.
Yarosh D, Alas LG, Yee V, Oberyszyn A, Kibitel JT, Mitchell D, Rosenstein R, Spinowitz A: Pyrimidine dimer removal enhanced by DNA repair liposomes reduces the incidence of UV skin cancer in mice. Cancer Res 1992;52:4227-4231.
32.
Yarosh D, Bucana C, Cox P, Alas L, Kibite, J, Kripke M: Localization of liposomes containing a DNA repair enzyme in murine skin. J Invest Dermatol 1994;104:461-468.
33.
Yarosh D, Klein J, O'Connor A, Hawk J, Rafal E, Wolf P: Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Lancet 2001;357:926-929.
34.
Stege H, Roza L, Vink AA, Grewe M, Ruzicka T, et al: Enzyme plus light therapy to repair DNA damage in ultraviolet-B-irradiated human skin. Proc Natl Acad Sci USA 2000;97:1790-1795.
35.
Stege H: Effect of xenogenic repair enzymes on photoimmunology and photocarcinogenesis. J Photochem Photobiol B 2001;65:105-108.
36.
Puviani M, Barcella A, Milani M: Eryfotona AK-NMSC in the treatment of cancerization field in patients with actinic keratosis or non-melanoma skin cancer: a report of six cases. G Ital Dermatol Venereol 2013;148(suppl 2):1-6.
37.
Giustini S, Miraglia E, Berardesca E, Milani M, Calvieri S: Preventive long-term effects of a topical film-forming medical device with ultra-high UV protection filters and DNA repair enzyme in xeroderma pigmentosum: a retrospective study of eight cases. Case Rep Dermatol 2014;6:222-226.
38.
Puig S, Puig-Butillé JA, Díaz MA, Trullas C, Malvehy J: Field cancerisation improvement with topical application of a film-forming medical device containing photolyase and UV filters in patients with actinic keratosis, a pilot study. J Clin Exp Derm 2014;5:1-7.
39.
Puig-Butille JM, Malvehy J, Potrony M, Trullas C, Joaquin Dopazo J, Puig S: Role of CPI-17 in restoring skin homoeostasis in cutaneous field of cancerization: effects of topical application of a film-forming medical device containing photolyase and UV filters. Exp Dermatol 2013;22:482-501.
40.
Rstom SA, Martinez B, Abdalla Z, Rezze GG, Paschoal FM: Avaliação da ação de creme contendo fotolíase em lipossomas e filtro solar FPS 100 na queratose actínica da face: estudo clínico, dermatoscópico e por microscopia confocal. Surg Cosmet Dermatol 2014;6:226-231.
41.
Shekelle PG, Woolf SH, Eccles M, Grimshaw J: Developing clinical guidelines. West J Med 1999;170:348-351.
42.
Premi S, Wallisch S, Mano CM, Weiner AB, Bacchiocchi A, Wakamatsu K, Bechara EJ, Halaban R, Douki T, Brash DE: Chemiexcitation of melanin derivatives induces DNA photoproducts long after UV exposure. Science 2015;347:842-847.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.